1 1

IGFBP-4 Protein, Human

IGFBP-4 Protein, Human

Catalog Number: UA040534 Brand: UA BIOSCIENCE
Share:
Price:
$120 USD
$120 USD
Size:

For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details

Product Details

Product Specification


Species Human
Synonyms Insulin-like growth factor-binding protein 4, IBP-4, IGF-binding protein 4, IGFBP-4
Accession P22692
Amino Acid Sequence

Asp22-Glu258 with His Tag at the C-Terminus
Expression System HEK293
Molecular Weight

35-38 kDa (Reducing)
Purity >95% by SDS-PAGE & HPLC.
Endotoxin <0.1EU/μg
Conjugation Unconjugated
Tag His Tag
Physical Appearance Lyophilized powder
Storage Buffer

PBS, 1mM EDTA, pH7.4
Reconstitution

Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
Stability & Storage

·12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
·3 months, -20 to -80℃ under sterile conditions after reconstitution.
·1 week, 2 to 8℃ under sterile conditions after reconstitution.
·Please avoid repeated freeze-thaw cycles.
Reference

J Clin Invest. 2008 Jul;118(7):2609-19.
Circ Res. 2000 Feb 4;86(2):125-30.

Background

Insulin-like Growth Factor Binding Protein-4 (IGFBP-4) is the smallest member of the IGFBP family, with a molecular weight of approximately 24 kDa, encoded by the IGFBP4 gene located on human chromosome 17q12-21.1. The protein consists of 237 amino acids and contains the conserved N-terminal, C-terminal, and variable L-domains characteristic of the IGFBP family, including two additional interconnected cysteine residues in the L-domain. IGFBP-4 binds both IGF-I and IGF-II with high affinity, exhibiting 2–10 fold higher affinity for IGF-II than for IGF-I. This binding prolongs IGF half-life and inhibits ligand-receptor interactions, thereby attenuating IGF-mediated proliferation and differentiation in most physiological contexts.

Picture

Bioactivity

Measured by its ability to inhibit the biological activity of IGFII on MCF7 human breast adenocarcinoma cells. The EC50 for this effect is typically 31-48ng/mL in the presence of 14 ng/mL human IGFII.

SDS-PAGE

2μg (R: reducing condition, N: non-reducing condition).

RP-HPLC

>95% as determined by RP-HPLC.